Directorate Change
September 05 2003 - 9:58AM
UK Regulatory
RNS Number:4544P
PPL Therapeutics PLC
05 September 2003
Date: Immediate, Friday 5 September 2003
Contact: Geoff Cook, Chief Executive Officer
PPL Therapeutics plc
Telephone: 0131 440 4777
Alistair Mackinnon-Musson
Philip Dennis
Hudson Sandler
Telephone: 020 7796 4133
Email: ppl@hspr.co.uk
PPL Therapeutics PLC
Board Change
The Board of PPL Therapeutics plc ("PPL") is disappointed to announce that Bill
McCall has decided to resign as a non-executive director of the Board with
immediate effect.
PPL is currently in the process of restructuring its business following the
decision of PPL and Bayer to put its recAAT programme on hold, as announced on
18 June 2003.
The Company is currently presenting the options available to it at this time to
its largest shareholders in order to secure their support for the future
strategic direction of the business.
Options being explored are to restructure as a business based around its Fibrin
I technology and to bring in complementary intellectual property to broaden the
product portfolio. Other alternatives being reviewed include the outright sale
of the Company or its winding up.
The Board of PPL aims to conclude these discussions as quickly as possible and
reach a conclusion on the best way forward to enhance value for all
shareholders.
- Ends -
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOAUUUQABUPWGWA